G
Guillermo Ruiz-Irastorza
Researcher at University of the Basque Country
Publications - 249
Citations - 19687
Guillermo Ruiz-Irastorza is an academic researcher from University of the Basque Country. The author has contributed to research in topics: Antiphospholipid syndrome & Systemic lupus erythematosus. The author has an hindex of 53, co-authored 225 publications receiving 15514 citations. Previous affiliations of Guillermo Ruiz-Irastorza include St Thomas' Hospital & Guy's and St Thomas' NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more
TL;DR: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
Journal ArticleDOI
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer,Karen H. Costenbader,David I. Daikh,Ralph Brinks,Marta Mosca,Rosalind Ramsey-Goldman,Josef S Smolen,David Wofsy,Dimitrios T. Boumpas,Diane L. Kamen,David Jayne,Ricard Cervera,Nathalie Costedoat-Chalumeau,Betty Diamond,Dafna D. Gladman,Bevra H. Hahn,Falk Hiepe,Søren Jacobsen,Dinesh Khanna,Kirsten Lerstrøm,Elena Massarotti,Joseph M. McCune,Guillermo Ruiz-Irastorza,Jorge Sanchez-Guerrero,Matthias Schneider,Murray B. Urowitz,George Bertsias,Bimba F. Hoyer,Nicolai Leuchten,Chiara Tani,Sara K. Tedeschi,Zahi Touma,Gabriela Schmajuk,Branimir Anić,Florence Assan,Tak Mao Chan,Ann E. Clarke,Mary K. Crow,László Czirják,Andrea Doria,Winfried Graninger,Bernadett Halda-Kiss,Sarfaraz Hasni,Peter M. Izmirly,Michelle Jung,Gábor Kumánovics,Xavier Mariette,Ivan Padjen,José M. Pego-Reigosa,Juanita Romero-Diaz,Íñigo Rúa-Figueroa Fernández,Raphaèle Seror,Georg Stummvoll,Yoshiya Tanaka,Maria G Tektonidou,Carlos Vasconcelos,Edward M Vital,Daniel J. Wallace,Sule Yavuz,Pier Luigi Meroni,Marvin J. Fritzler,Ray Naden,Thomas Dörner,Sindhu R. Johnson +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
TL;DR: High levels of evidence were found that AMs prevent lupus flares and increase long-term survival of patients with SLE; moderate evidence of protection against irreversible organ damage, thrombosis and bone mass loss and evidence supporting an effect on severe l upus activity, lipid levels and subclinical atherosclerosis was weak.
Book
Systemic Lupus Erythematosus
TL;DR: A review of major advances in clinical issues related to systemic lupus erythematosus (SLE) published between 1995 and 2000 can be found in this paper, where the authors discuss the role of cyclophosphamide, methotrexate, antimalarials, and hormonal treatment in the management of SLE.
Journal ArticleDOI
Systemic lupus erythematosus.
Arvind Kaul,Caroline Gordon,Mary K. Crow,Zahi Touma,Murray B. Urowitz,Ronald F van Vollenhoven,Guillermo Ruiz-Irastorza,Graham R. V. Hughes +7 more
TL;DR: The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucose-sparing regimes.